Cyano-Irbesartan CAS 138401-24-8 Purity >98.0% (HPLC) Irbesartan Intermediate Factory
Ruifu Chemical Supply Irbesartan Intermediates:
Irbesartan CAS 138402-11-6
Cyano-Irbesartan CAS 138401-24-8
Trityl Irbesartan CAS 138402-10-5
TTBB CAS 124750-51-2
Irbesartan Side Chain Hydrochloride CAS 151257-01-1
Chemical Name | Cyano-Irbesartan |
Synonyms | CyanoIrbesartan; Irbesartan Cyano Impurity; Irbesartan Hydrocarbon; Irbesartan Impurity 6; 2-Butyl-3-[[2'-cyano-[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4,4]non-1-en-3-yl)methyl]-[1,1'-biphenyl]-2-carbonitrile |
CAS Number | 138401-24-8 |
CAT Number | RF-PI1892 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C25H27N3O |
Molecular Weight | 385.51 |
Density | 1.15 |
Solubility (Soluble in) | Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Almost White Powder to Crystal |
Purity / Analysis Method | >98.0% (HPLC) |
Purity | >97.0% (With Total Nitrogen) |
Melting Point | 91.0 to 95.0℃ |
Loss on Drying | <1.00% |
Single Impurity | <1.00% |
Heavy Metals | <20ppm |
Infrared Spectrum | Conforms to Structure |
Test Standard | Enterprise Standard |
Usage | Intermediate / Impurity of Irbesartan (CAS: 138402-11-6) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Cyano-Irbesartan (CAS: 138401-24-8) is an intermediate or impurity of Irbesartan (CAS: 138402-11-6). Irbesartan is an angiotensin II (Angiotensin II, Ang II) receptor inhibitor. Angiotensin II receptors are divided into two types: AT1 and AT2. Irbesartan selectively blocks the AT1 receptor of AnglI. It can inhibit the conversion of Ang into Ang, can specifically antagonize the angiotensin-converting enzyme 1 receptor (AT1). The antagonistic effect on AT1 is 8500 times that of AT2. It can selectively block the binding of Ang and AT1 receptor through Inhibit vasoconstriction and the release of aldosterone, resulting in a hypotensive effect. This product does not inhibit angiotensin converting enzyme (ACE), renin, other hormone receptors, nor does it inhibit ion channels related to blood pressure regulation and sodium balance. Irbesartan can also reduce the electrical remodeling of the myocardium, thereby reducing the fatality rate of patients with hypertension. It is currently the most effective drug for the treatment of hypertension and cardiovascular diseases.